Table 2. Univariate and multivariate analyses for OS after recurrence.

Variables	Univariate analysis			Multivariate analysis
	HR (95% CI)	P		HR (95% CI)	P
OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval.
Age at recurrence	1.009 (1.001−1.017)	0.035		1.003 (0.994−1.012)	0.521
Gender		0.827
Male	Reference
Female	1.024 (0.830−1.263)
Differentiation		0.322
Well/moderate	Reference
Poorly/signet ring cell	1.100 (0.911−1.329)
T stage		0.005			0.300
T1−2	Reference			Reference
T3	1.510 (1.032−2.209)			1.358 (0.910−2.028)
T4a	1.777 (1.229−2.571)			1.261 (0.830−1.915)
N stage		<0.001			0.004
N0	Reference			Reference
N1	1.371 (0.872−2.156)			1.535 (0.970−2.429)
N2	1.749 (1.179−2.595)			1.933 (1.281−2.918)
N3a	1.886 (1.307−2.721)			1.845 (1.245−2.736)
N3b	2.329 (1.597−3.396)			2.235 (1.476−3.386)
Tumor size	1.005 (1.001−1.008)	0.008		1.001 (0.997−1.006)	0.572
Tumor location		0.605
Lower	Reference
Middle	1.127 (0.882−1.441)
Upper	1.070 (0.842−1.361)
Mixed	1.183 (0.908−1.543)
Lymphovascular invasion		0.160
No	Reference
Yes	1.141 (0.949−1.372)
Neural invasion		0.676
No	Reference
Yes	1.043 (0.856−1.270)
Adjuvant chemotherapy		0.025			0.881
No	Reference			Reference
Yes	0.793 (0.648−0.971)			0.983 (0.784−1.233)
Symptom(s) of recurrence		<0.001			<0.001
Asymptomatic	Reference			Reference
Symptomatic	2.044 (1.666−2.507)			2.027 (1.637−2.510)
No. of metastasis site(s)		0.002			<0.001
1 site	Reference			Reference
≥2 sites	1.375 (1.129−1.675)			1.544 (1.257−1.896)
Time of recurrence		0.018			0.037
Within 1 years	Reference			Reference
≥1 years	0.795 (0.657−0.961)			0.808 (0.661−0.987)
Treatment of recurrence		<0.001			<0.001
Support treatment only	Reference			Reference
Potential curative treatment	0.288 (0.234−0.355)			0.265 (0.211−0.333)